LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Omeros Corp

Fechado

SetorSaúde

4.25 0.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.14

Máximo

4.26

Indicadores-chave

By Trading Economics

Rendimento

8M

-25M

Margem de lucro

-8,121.359

Funcionários

202

EBITDA

9.3M

-26M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+113.78% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.2M

283M

Abertura anterior

3.3

Fecho anterior

4.25

Sentimento de Notícias

By Acuity

60%

40%

328 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Omeros Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de set. de 2025, 23:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 de set. de 2025, 22:02 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 de set. de 2025, 17:01 UTC

Grandes Movimentos do Mercado

Tron Shares Rise After New Investment From Bravemorning

8 de set. de 2025, 16:14 UTC

Grandes Movimentos do Mercado

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 de set. de 2025, 16:13 UTC

Grandes Movimentos do Mercado

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de set. de 2025, 23:12 UTC

Conversa de Mercado

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 de set. de 2025, 22:56 UTC

Conversa de Mercado

Worst May Be Over for New Zealand Retailers -- Market Talk

8 de set. de 2025, 22:23 UTC

Conversa de Mercado

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 de set. de 2025, 21:51 UTC

Conversa de Mercado

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 de set. de 2025, 21:47 UTC

Grandes Movimentos do Mercado

Microsoft Signs $17.4B AI Deal With Nebius

8 de set. de 2025, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 de set. de 2025, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 de set. de 2025, 21:19 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 de set. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 19:33 UTC

Conversa de Mercado

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 de set. de 2025, 19:22 UTC

Conversa de Mercado

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 de set. de 2025, 19:02 UTC

Conversa de Mercado

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de set. de 2025, 18:24 UTC

Conversa de Mercado

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 de set. de 2025, 17:29 UTC

Conversa de Mercado

Mexican Inflation Seen Little Changed in August -- Market Talk

8 de set. de 2025, 16:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 de set. de 2025, 16:36 UTC

Conversa de Mercado

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 de set. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de set. de 2025, 16:16 UTC

Ganhos

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de set. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Omeros Corp Previsão

Preço-alvo

By TipRanks

113.78% parte superior

Previsão para 12 meses

Média 9 USD  113.78%

Máximo 9 USD

Mínimo 9 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Omeros Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.265 / 7.49Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

328 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat